R&D Story
GC Biopharma’s researchers
Continue to rise
To the challenge of saving lives.
Third-Generation Recombinant Factor VIII Treatment for Hemophilia
Greengene F
Greengene F is a third-generation gene recombination therapy for hemophilia A, successfully developed by GC Biopharma, marking the third time globally. This product embodies the excellent technological prowess and know-how of GC Biopharma. Phase three clinical trials have been completed in China, which resulted in product approval in 2021. GC Biopharma is also striving to develop next-generation hemophilia treatments that treat patients with hemophilia A and B and antibody-producing patients by targeting novel blood coagulation mechanisms. GC Biopharma plans to expand its pipeline of blood disorder treatments in the domestic market and increase its market share worldwide.
World-Class Quality
Plasma Derivatives
GC Biopharma remains committed to improving the products that have already received government and market approval. This commitment ensures an improvement in quality and diversifying dosages and types. IVIG-SN, human normal immunoglobulin for immunodeficiency, has obtained approval in 15 countries worldwide and is receiving growing demand in South America and elsewhere. IVIG-SN successfully completed its Phase 3 clinical trial in the United States. GC Biopharma expects to launch IVIG-SN in the United States marketplace shortly.
A Pioneer in the Global Vaccine Market
Oncology, Immunology, and Cell Therapy
In 2014, GC Biopharma achieved the development of Neulapeg, a treatment for neutropenia. Designed as a supplement for immunosuppressant chemotherapy, Neulapeg effectively mitigates the side effects of the treatment. Additionally, it offers a longer half-life compared to its first-generation counterpart. This advancement has enabled the Korean medical community to discontinue importing similar drugs from overseas. Furthermore, GC Biopharma is working on introducing an innovative antibody production technology and will continue researching and developing new candidate materials for immunotherapy for cancer patients. Its specialized subsidiaries are also helping the company strengthen its position in cell therapy, which is emerging as a new potential source of economic growth.
Restoring Hope to People
with Rare Diseases
Rare Disease Treatments
At GC Biopharma, we believe it is our duty to research and develop treatments for rare diseases. Despite how difficult they are to make or how limited their market prospect is, they play a crucial role in saving lives. The first sign of success started in 2012 and came in the form of Hunterase, a treatment for Hunter syndrome, a hereditary metabolic disorder known as mucopolysaccharidosis (MPS) type-II. Developed as the second Hunter syndrome treatment globally, Hunterase has helped reduce the financial burden on Korean patients and their families by replacing the more expensive imported alternative and significantly improving their quality of life. Under GC Biopharma's plan to bring this innovative drug to Hunter syndrome patients around the world; it has been introduced into eight South American and North African markets. Hunterase was approved in China in 2020. and it is currently under clinical trials in many countries.
Future Strategy
GC Biopharma has been accumulating expertise in plasma derivatives, vaccines, and recombinant proteins. In the process, the company has made significant impact on treatment for patients and on public health. GC Biopharma is now ready to maximize and upgrade the values of its existing products, and engage in strategic R&D activities to further strengthen its pipeline of products against a wider range of diseases.
-
- GC MS
- GC Wellbeing
- GCMedis
-
- Overseas
- GC China Pharm
- Curevo
- GC Pharma do Brasil
-
- Foundation
- MOGAM Institue
- GC Labs
- GC i-Med
-
- Others
- GC Invacfarm